Results 151 to 158 of about 50,070 (158)

Identifying resonant frequencies of viruses for microwave-based detection and inactivation of pathogenic viruses. [PDF]

Sci Rep
Kuang Z, Luginsland J, Hung CS, Stamps BW, Thomas RJ, Kelley-Loughnane N, Ruiz ON, Roach WP.   +7 more
europepmc   +1 more source

Optimization of VE607 to generate analogs with improved neutralization activities against SARS-CoV-2 variants. [PDF]

J Virol
Ding S, Yang D, Ullah I, Niu L, Unger M, Díaz-Salinas MA, Chandravanshi M, Zhou F, Beaudoin-Bussières G, Benlarbi M, Tolbert WD, Yoon K-W, Xu R, Laroche G, Gaudette F, Morton AJ, Lang ZC, Son A, Abrams C, Côté M, Smith AB, Huang RK, Matthies D, Munro JB, Pazgier M, Uchil PD, Finzi A.   +26 more
europepmc   +1 more source

Immunogenicity of JN.1 and KP.2 COVID-19 mRNA vaccines against emerging SARS-CoV-2 variants. [PDF]

Vaccine
Lasrado N, Rössler A, McConnell I, Molloy K, Bhowmik R, Happle C, Guan R, McMahan K, Pereira J, Liu J, Borducchi E, Wang L, Shah K, Wixted B, Stankov MV, Dopfer-Jablonka A, Collier AY, Behrens GMN, Barouch DH.   +18 more
europepmc   +1 more source

A HiBiT-tagged pseudovirus-like particle platform for safe, rapid quantification of virus neutralization and antibody-dependent enhancement. [PDF]

J Virol
Mitchell JK, Mastrodomenico V, Hartnett J, Heelan WJ, Garvin D, Cong M, Grailer JJ.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Structural Bioinformatics to Unveil Weaknesses of Coronavirus Spike Glycoprotein Stability

2021
Alternative strategies for developing antiviral drugs are needed, as vaccines could not be the final answer against the present SARS CoV-2 outbreak, due to the still existing ambiguities in the immunological response to the virus. Thus, SARS CoV-2 enzymes have been thoroughly investigated to develop their inhibitors as antiviral drugs. We have searched
Bongini P., Trezza A., Bianchini M., Spiga O., Niccolai N.   +4 more
openaire   +2 more sources

Core Structure of S2 from the Human Coronavirus NL63 Spike Glycoprotein^,

Biochemistry, 2006
Human coronavirus NL63 (HCoV-NL63) has recently been identified as a causative agent of acute respiratory tract illnesses in infants and young children. The HCoV-NL63 spike (S) protein mediates virion attachment to cells and subsequent fusion of the viral and cellular membranes.
Zheng, Qi, Deng, Yiqun, Liu, Jie, van der Hoek, Lia, Berkhout, Ben, Lu, Min   +5 more
openaire   +2 more sources

Spike glycoprotein of coronavirus of animals and sars-Cov-2

Indian Journal of Comparative Microbiology, Immunology and Infectious Diseases, 2022
Bramhadev Pattnaik, Suresh Puttahonnappa Kuralayanapalya, Chandan Shivamallu, Shiva Prasad Kollur, Mahendra P. Yadav, Siju Susan Jacob, Awadh B. Pandey, Kirankere Ananthapadmanabha Shyamsundar, Sharanagouda S. Patil   +8 more
openaire   +1 more source

BPS2025 - Characterization of bat coronavirus spike glycoprotein dynamics via molecular dynamics simulations

Biophysical Journal
Toheeb A. Balogun, Cory M. Acreman, Fiona L. Kearns, Alexandra L. Tse, Gorka Lasso, Emily H. Miller, Kartik Chandran, Jason S. McLellan, Rommie E. Amaro   +8 more
openaire   +1 more source